Short answer
Intellia Therapeutics, Inc. (NTLA) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15M (down 9.5% year over year) with net income of −$96M.
Q1 2026 key financials · XBRL
- Revenue
- $15M
- −9.5% YoY
- Net income
- −$96M
- +15.8% YoY
- Operating margin
- -668.1%
- EPS (diluted)
- −$0.81
- +26.4% YoY
Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) Q1 2026 10-Q on SEC EDGAR. USD.
Intellia Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $15.0M, down $1.6M YoY from $16.6M
- Operating loss $100.5M vs $120.8M YoY; net loss $96.2M vs $114.3M
- Nex-z development spending $20.2M vs $23.1M; lonvo-z $8.1M vs $10.7M
- Cash, equivalents and marketable securities $517.2M; ATM proceeds $33.6M from 2.6M shares
- BLA submission expected second half 2026; potential lonvo-z U.S. launch first half 2027
Risk Factors
- Newly added technology risk: first-in-pivotal-trial in vivo CRISPR candidates remain clinically unproven despite recent human validation
- Regulatory risk: FDA lifted MAGNITUDE and MAGNITUDE-2 clinical holds in Q1 2026 after Grade 4 liver injury and patient death
- Clinical-development risk: additional FDA toxicology, biodistribution, or reproductive-health studies could delay BLA submissions
- Operational risk: manufacturing delays or inadequate supplies could disrupt nex-z and lonvo-z clinical-trial timelines
- Financial risk: continued net losses and no product-sales revenue could prevent profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Intellia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.